Article Text

Download PDFPDF
Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy

Statistics from Altmetric.com

Footnotes

  • Twitter @julian_hong

  • Contributors MG and JH drafted the manuscript and all authors provided critical revisions. All authors provided final approval of the manuscript and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JH is coinventor on a pending patent unrelated to this manuscript. FYF has paid consultant/advisory board relationships with Janssen, Sanofi, Astellas, Bayer, Genentech, EMD Serono, Clovis and Celgene, and an unpaid consultant/advisory board relationship with PFS Genomics.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.